Beta Bionics Stock

betabionics.comHealthcare / Medical DevicesFounded: 2015Funding to Date: $132MM

Beta Bionics, founded in 2015, is a medical technology company, and the creator of a bionic pancreas that aims to make diabetes care more manageable. Their iLet Bionic Pancreas is an automated insulin delivery system that can calculate doses, aiming to reduce the need for users to make decisions about their diabetes management.

Register To Buy and Sell Shares

For more details on financing and valuation for Beta Bionics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Beta Bionics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Beta Bionics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Toby Milgrome
Edward Damiano
Founder, President & Chief Executive Officer
Firas El-Khatib Ph.D
Co-Founder & Vice President, Autonomous Systems
Serafina Raskin
Vice President, Corporate Secretary & General Counsel
Stephen Feider
Chief Financial Officer
Steve Russell Ph.D
Chief Medical Officer

Board Members

Christian Foged
Novo Nordisk
Finny Kuruvilla Ph.D
Eventide Asset Management

Beta Bionics’ stock FAQs


Can you buy Beta Bionics’ stock?

Beta Bionics is not publicly traded on NYSE or NASDAQ in the U.S. To buy Beta Bionics’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.

Can you sell Beta Bionics’ stock?

Yes, you can sell stock of a private company like Beta Bionics. Forge can help you sell your Beta Bionics stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.

What is Beta Bionics’ stock price?

Beta Bionics is a privately held company and therefore does not have a public stock price. However, you may access Beta Bionics’ private market stock price with Forge Data.

What is Beta Bionics’ stock ticker symbol?

Beta Bionics does not have an official ticker symbol because this company is not currently publicly traded.

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Beta Bionics brings in $100M to expand artificial pancreas tech after FDA nod

In the wake of earning FDA clearance for its insulin pump and automated dosing software—which connect to a Dexcom continuous glucose monitor to create what’s known as a hybrid closed-loop system for diabetes management—Beta Bionics is raking in the dough. The Massachusetts-based company has pooled $100 million in series D equity funding, it announced this week.

FDA clears Beta Bionics' insulin pump and automated dosing software to create artificial pancreas

Artificial pancreas systems synchronize an insulin pump and continuous glucose monitor with the goal of delivering an almost completely hands-off approach to diabetes management—and the newest one cleared by the FDA aims to make that goal even easier to achieve.

Beta Bionics Receives FDA Breakthrough Device Designation for the iLet™ Bionic Pancreas System

The iLet is a pocket-sized, wearable investigational medical device that autonomously controls blood sugar in people with diabetes and other conditions --...
Updated on: Jul 17, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.